Posted on: 3 March 2025, source: hcplive.com
Pfizer has announced that it is discontinuing development and commercialization of fidanacogene elaparvovec an adeno-associated virus (AAV) vector-based gene therapy for the treatment of hemophilia B. The therapy was approved by the FDA under the name Beqvez less than a year ago, in April 2024. Reuters reported the news on February 21, stating that Pfizer cited limited interest in gene therapies for hemophilia as a reason for discontinuation. No patients had been dosed yet in the commercial setting with the therapy, which was priced at a whopping $3.5 million.